CD4+Foxp3+ regulatory T lymphocytes expressing CD62L in patients with long-standing diabetes type 1

Central-European Journal of Immunology

Volumn 34, Issue 2, 2009, Pages 90-93

  Ryba, Monika ^a   Hak, Łukasz ^a   Zorena, Katarzyna ^a   Myoeliwiec, Małgorzata ^a   Myoeliwska, Jolanta ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

CD62L; Diabetes type 1; Foxp3; Regulatory T cells

Indexed keywords

CD3 ANTIBODY; CD4 ANTIGEN; L SELECTIN; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 70349619401     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bach JF, Chatenoud L (2001): Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 19: 131-161.
2. Hori S, Takahashi T, Sakaguchi S (2003): Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 81: 331-371.
3. Hori S, Nomura T, Sakaguchi S (2003): Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
4. Fontenot JD, Gavin MA, Rudensky AY (2003): Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330-336.
5. Brusko TM Putnam AL, Bluestone JA (2008): Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 223: 371-390.
6. Arbones ML, Ord DC, Ley K et al. (1994): Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity 1: 247-260.
7. Szanya V, Ermann J, Taylor C et al. (2002): The subpopulation of CD4+CD25+splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 169: 2461-2465.
8. Ermann J, Hoffmann P, Edinger M et al. (2005): Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 105: 2220-2226.
9. Taylor PA, Panoskaltsis-Mortari A, Swedin JM et al. (2004): L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104: 3804-3812.
10. Kim CH (2006): Migration and function of FoxP3+ regulatory T cells in the hematolymphoid system. Exp Hematol 34: 1033-1040.
11. Lepault F, Gagnerault MC (2000): Characterization of Peripheral Regulatory CD4+ T Cells That Prevent Diabetes Onset in Nonobese Diabetic Mice. J Immunol 164: 240-247.
12. Brusko T, Wasserfall C, McGrail K et al. (2007): No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 56: 604-612.
13. Pop SM, Wong CP, He Q et al. (2007): The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes 56: 1395-1402.
14. Brusko TM, Wasserfall CH, Clare-Salzler MJ et al. (2005): Functional defects and the influence of age on the frequency of CD4+CD25+ T-cells in type 1 diabetes. Diabetes 54: 1407-1414.
15. Fu S, Yopp AC, Mao X et al. (2004): CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant 4: 65-78.
16. Thornton AM, Shevach EM (2000): Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 164: 183-190.
17. Kukreja A, Cost G, Marker J et al. (2002): Multiple immunoregulatory defects in type-1 diabetes. J Clin Invest 109: 131-140.
18. Baecher-Allan C, Viglietta V, Hafler DA (2004): Human CD4+ CD25+ regulatory T cells. Semin Immunol 16: 89-97.
19. American Diabetes Association (2003): Diagnosis and Classification of Diabetes. Diabetes Care 26: 3160-3167.